Email Updates

You are here

Home»Media

AVAC in the News

  • This Year’s AIDS Conference Has Brought Snippets of Good News

    Even in the days of the internet, conferences remain the lifeblood of science. Young thrusters can meet old fogeys and lobby them for jobs. Ideas can be swapped in the knowledge that no electronic trail will come back to haunt you. And journalists can swoop, scoop up a bundle of interesting stories and, with luck, provide an update to their readers and viewers of developments in whatever field the conference was about.

    July 8, 2020
    Cure, PrEP, Treatment
    The Economist

  • Researchers Highlight Importance of Youth, Women in HIV Prevention Research

    Researchers discussed HIV prevention research during a press conference at the AIDS 2020 meeting, highlighting the importance of involving young people and women. The event included perspectives from various researchers on successful interventions and disruptions to treatment because of the COVID-19 pandemic.

    July 8, 2020
    Microbicides, PrEP
    Healio

  • Confronting Missed Targets, HIV/AIDS Experts Emphasize Drug Delivery

    The conversation at AIDS 2020 is focusing not just on developing new technologies to fight HIV/AIDS — but also ensuring the tools that already exist realize their potential for impact. As the world falls short of 2020 targets for progress on HIV/AIDS, global health experts are highlighting the need to make testing, prevention, and treatment affordable and accessible.

    July 8, 2020
    PrEP, Treatment
    Devex

  • This Injection Outperforms a Daily Pill to Prevent HIV Infection. Will You Use It?

    An injection every two months is three times more effective in preventing HIV infection among men and transgender women than a daily prevention pill.

    July 8, 2020
    PrEP
    Bhekisisa

  • New Law Aims to Expand Access to HIV Prevention — But Will It?

    Back in March, Quadeer Jones, a 23-year-old actor in Los Angeles, decided to get pre-exposure prophylaxis, or PrEP, to protect himself from HIV when having sex. He made an appointment at the Los Angeles LGBT Center to get PrEP medication, the antiretroviral Truvada, traveling more than 30 miles. Once he arrived at the center, the process was relatively easy. “I had to schedule an appointment for rapid HIV testing,” he says. “They said I was negative. I got my prescription and meds and I was out the door in about an hour.”

    July 7, 2020
    PrEP
    Capital & Main

  • Investigational PrEP Injection, Dosed Every Other Month, Beats Daily PrEP in Phase 3 Study

    Taken every 2 months, the long-acting injectable drug cabotegravir (CAB-LA) prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study. The results were released originally in May due to the overwhelmingly positive data on CAB-LA for PrEP, but researchers presented their final data in early July at the 23rd International AIDS Conference (AIDS 2020).

    July 7, 2020
    PrEP
    The BodyPro

  • Can This New Injectable Deliver on Its Promise to Reduce HIV Transmission?

    New clinical evidence shows that cabotegravir, an investigative injectable drug under development for HIV prevention and treatment, is 66 percent more effective than oral preexposure prophylaxis.

    July 7, 2020
    PrEP
    Devex

  • Partnership Science

    Mark Feinberg and Helen Rees joined Mitchell Warren for a webinar titled “Pandemic Vaccine Development and Lessons for COVID-19” in April 2020. It is part of the COVID-19 and HIV webinar series hosted by AVAC, which focuses on global advocacy for HIV prevention.

    June 29, 2020
    General
    POZ

  • Easier and Equitable Access to PrEP: How DSD Can Help Get Us There

    Improving access to HIV prevention is critical if we want to see meaningful reductions in new infections. Although the adoption and use of oral pre-exposure prophylaxis (PrEP) has gradually increased, with an estimated half a million people initiating PrEP worldwide, we are far from achieving the global target of three million users by the end of 2020.

    June 24, 2020
    PrEP
    Differentiated Service Delivery

  • The Dangers of Excluding Women From HIV Prevention Drug Tests

    When Dázon Dixon Diallo began working to prevent the spread of HIV among women in 1985, she first had to convince them that they could get the infection. Even some HIV activists didn’t fully appreciate that women needed to be included in prevention efforts. Diallo founded an Atlanta-based organization called SisterLove to promote reproductive justice and to support women with or at risk of getting HIV/AIDS, expanding it to a program in South Africa, where today two-thirds of the people living with HIV are women. In the US, almost one in five new HIV diagnoses are among women.

    June 10, 2020
    PrEP
    Wired

Pages